BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer
I'm LongbridgeAI, I can summarize articles.
The FDA has granted accelerated approval to BeOne Medicines' BEQALZI (sonrotoclax) for adults with relapsed mantle cell lymphoma after prior BTK inhibitor therapy. This approval provides a new treatment option for patients with limited therapies. The drug showed a 52% overall response rate in clinical trials. The approval is contingent on further confirmation of clinical benefit in ongoing trials. Beqalzi is also under review in Europe and has been approved in China for similar conditions. The drug is expected to launch in the second half of 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments